The Application Progress of Selinexor in the Treatment of Relapsed and Refractory Multiple Myeloma--Review.
10.19746/j.cnki.issn.1009-2137.2025.04.046
- Author:
Yu-Xin TONG
1
;
Ya-Min TAN
1
Author Information
1. Department of Hematology, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China.
- Publication Type:English Abstract
- Keywords:
selinexor;
relaspsed refractory multiple myeloma;
application progress;
adverse reaction
- MeSH:
Humans;
Multiple Myeloma/drug therapy*;
Hydrazines/therapeutic use*;
Triazoles/therapeutic use*;
Quality of Life;
Recurrence
- From:
Journal of Experimental Hematology
2025;33(4):1233-1236
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma is a common and refractory hematological malignancy for which there is currently no radical treatment, and it is prone to relapse. Patients with relapsed and refractory myeloma have often been previously treated with multiple drugs including proteasome inhibitors and / or immunomodulatory drugs. Therefore, for such patients, the primary goal of treatment is to achieve disease control with acceptable toxicity and maintenance of quality of life. In this paper, the aim is to review the clinical effect of selinexor in treating patients with RRMM. As a novel treatment for RRMM, selinexor has a unique pharmacological mechanism that may further improve the clinical response rate of RRMM patients and enhance patients' quality of life. Although selinexor can cause a series of adverse reactions, most of these adverse reactions can be alleviated or disappear after clinical targeted treatment, and effective preventive measures can also minimize the occurrence of adverse reactions. In conclusion, selinexor has shown broad application prospects in RRMM patients, and further research will be conducted in the future to optimize the treatment regimen of selinexor, so that more RRMM patients can benefit from it.
